Policy

Despite their profound sacrifices, veterans and active military members disproportionately face significant physical and mental health issues stemming from their service, with many struggling to access the affordable and comprehensive care they need.

It is unclear whether Congress would pass a law to codify or expand on the Mental Health Parity and Addiction Equity Act should the federal rule be appealed by the Trump administration, according to Ali Khawar.

Congress is unlikely to codify the recent executive order to lower drug pricing as other US officials negotiate new prices, John Barkett, MBA, of Berkeley Research Group, explains.

This week, the Center on Health Equity & Access covered news from the Trump administration and CMS, Cigna's co-pay cap on weight loss drugs, and perspectives on living with HIV.

The Make Our Children Healthy Again assessment from the Make America Healthy Again (MAHA) Commission warns of a national childhood health crisis and calls for broad federal reforms.

The immediate impact of the recent executive order aimed at lowering drug prices is likely low, as it may take until 2027 before actions detailed in the order can be enacted.

The executive order that President Donald Trump signed to lower drug prices could come under legal challenges by the drug industry.

Following President Donald Trump's most favored nation executive order, HHS and CMS have released the target price for pharmaceutical manufacturers to meet.

HHS announces it is taking steps to implement President Trump’s Executive Order on prescription drug pricing. Keep up with the latest moves made in health policy under President Donald Trump's second administration. This timeline will be updated as orders and policy progress.

In an era that FDA Commissioner Marty Makary, MD, MPH, calls an "epidemic of distrust" toward health institutions, previously contained disease rates are rapidly rising, and vaccination rates are proceeding in the opposite direction.

The executive order signed on May 12 has some differences from a previous executive order originally signed by the Trump administration in 2020.

A new analysis looked at estimated out-of-pocket costs for etanercept, ustekinumab, and ibrutinib, specialty drugs that often represent a significant cost burden for Medicare Part D beneficiaries and which were selected for 2026 drug price negotiation under the Inflation Reduction Act.

The new executive order contains multiple provisions if pharmaceutical companies do not offer "most-favored nation" pricing on medication.

Employers explore innovative strategies at the Greater Philadelphia Business Coalition on Health (GPBCH) Annual Conference, focusing on GLP-1 policies to enhance health care quality and manage costs effectively.

Robert F. Kennedy Jr’s congressional hearing featured numerous statements from the secretary of HHS, including denouncing claims of cutting down the HHS and the National Institutes of Health.

Investing in patient navigation and clinician incentives ensures colorectal cancer screening completion, improves early detection, reduces disparities, achieves cost savings, and advances population health for all stakeholders.

The Trump administration has decided to further debate the federal rule passed during the Biden administration that guaranteed insurance coverage for treatment of mental illness and substance abuse.

Proposed Medicaid cuts in the Republican budget proposal hold significant implications for health care access and coverage.

New studies reveal unmet health care needs and racial disparities, while experts share insight on addressing food insecurity and the shifting health policy landscape.

The move would align prescription costs in the US with the costs of other countries, according to the administration.

Antoine Keller, MD, argued the value of grounding health care policy in equity as clinicians prepare for a changing health care landscape in the coming years.

The Trump administration's termination of 694 NIH grants totaled $1.81 billion by April 2025, generating significant uncertainty and concern regarding the future of US health research, especially for minority populations.

The Ensuring Community Access to Pharmacist Services (ECAPS) Act of 2025 (H.R. 3164) aims to ensure vital pharmacy services and access to care for underserved communities.

The National Comprehensive Cancer Network (NCCN) policy summit highlighted the need for improved communication between oncology and primary care to enhance cancer survivor outcomes and care transitions.

The FDA's decision to appoint Vinay Prasad, MD, MPH, to head its Center for Biologics Evaluation and Research (CBER) raised concerns over regulatory scrutiny as the biotech market dropped.